This Advisory can help clinicians who work in a mental health facility implement a tobacco cessation program to reduce the use of tobacco-related products and tobacco-related diseases among clients with SMI.
This advisory summarizes data on the use of sublingual and transmucosal buprenorphine for the medication-assisted treatment of opioid use disorder.
This advisory defines attention deficit hyperactivity disorder in adults, and explains interactions with substance use disorders.
This advisory reviews diabetes and how it relates to mental illness, stress, and substance use disorders. It highlights ways to integrate diabetes care into behavioral health treatment, such as screening and intake, staff education, integrated care, and counseling support.
This advisory answers questions about the seriousness of prescription drug misuse. It explains how people become dependent on prescription drugs, and treatment options. The advisory also offers necessary treatment resources for professionals.
This advisory gives substance use treatment and service providers updated facts about OxyContin. It describes its use and misuse, addiction and dependency, withdrawal symptoms, and treatment and detoxification protocols, including medication-assisted treatment.
Millions of Americans have a substance use disorder. Find a treatment facility near you.
Free and confidential support for people in distress, 24/7.
Find treatment facilities confidentially and anonymously, 24/7.
Treatment referral and information, 24/7.